Home LiteratureArticle Details
PMID: 19179289 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P

Abstract

Mammalian cells employ numerous innate cellular mechanisms to inhibit viral replication and spread. Tetherin, also known as Bst-2 or CD317, is a recently identified, IFN-induced, cellular response factor that blocks release of HIV-1 and other retroviruses from infected cells. The means by which tetherin retains retroviruses on the cell surface, as well as the mechanism used by the HIV-1 accessory protein Vpu to antagonize tetherin function and promote HIV-1 release, are unknown. Here, we document that tetherin functions as a broadly acting antiviral factor by demonstrating that both human and murine tetherin potently inhibit the release of the filovirus, Ebola, from the surface of cells. Expression of the Ebola glycoprotein (GP) antagonized the antiviral effect of human and murine tetherin and facilitated budding of Ebola particles, as did the HIV-1 Vpu protein. Conversely, Ebola GP could substitute for Vpu to promote HIV-1 virion release from tetherin-expressing cells, demonstrating a common cellular target for these divergent viral proteins. Ebola GP efficiently coimmunoprecipitated with tetherin, suggesting that the viral glycoprotein directly interferes with this host antiviral factor. These results demonstrate that tetherin is a cellular antiviral factor that restricts budding of structurally diverse enveloped viruses. Additionally, Ebola has evolved a highly effective strategy to combat this antiviral response elicited in the host during infection.

MeSH Terms
Animals Antigens, CD/metabolism,physiology Cell Line Ebolavirus/physiology Enzyme-Linked Immunosorbent Assay Filoviridae/growth & development,physiology GPI-Linked Proteins Glycoproteins/metabolism,physiology Humans Membrane Glycoproteins/metabolism,physiology Mice Microscopy, Electron, Scanning Protein Binding Viral Proteins/metabolism,physiology
Chemicals
Antigens, CD BST2 protein, human GPI-Linked Proteins Glycoproteins Membrane Glycoproteins Viral Proteins
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kaletsky Rachel L
Department of Microbiology, School of Medicine, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104-6076, USA.
Francica Joseph R
Agrawal-Gamse Caroline
Bates Paul
References (28)
28 references, click to expand
  1. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling.
    J Virol. 2006 Jun;80(11):5168-78 PMID: 16698997
  2. Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses.
    Virus Genes. 1999;18(2):183-7 PMID: 10403706
  3. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.
    J Virol. 2003 Dec;77(24):13433-8 PMID: 14645601
  4. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.
    PLoS Pathog. 2006 May;2(5):e39 PMID: 16699598
  5. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.
    Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6 PMID: 11095724
  6. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.
    J Virol. 1998 Aug;72(8):6442-7 PMID: 9658086
  7. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology.
    Virol J. 2006 May 23;3:31 PMID: 16719918
  8. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Nat Med. 2000 Aug;6(8):886-9 PMID: 10932225
  9. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.
    Traffic. 2003 Oct;4(10):694-709 PMID: 12956872
  10. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Cell Host Microbe. 2008 Apr 17;3(4):245-52 PMID: 18342597
  11. Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function.
    J Virol. 1999 Feb;73(2):1419-26 PMID: 9882347
  12. Drying cells for SEM, AFM and TEM by hexamethyldisilazane: a study on hepatic endothelial cells.
    J Microsc. 1997 Apr;186(Pt 1):84-7 PMID: 9159923
  13. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
    J Virol. 2005 Mar;79(6):3627-38 PMID: 15731257
  14. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry.
    Cell Immunol. 2005 Jul-Aug;236(1-2):6-16 PMID: 16157322
  15. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.
    J Virol. 1996 Apr;70(4):2669-73 PMID: 8642705
  16. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.
    J Virol. 2002 Mar;76(5):2518-28 PMID: 11836430
  17. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer.
    Virology. 1998 Oct 25;250(2):408-14 PMID: 9792851
  18. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles.
    J Virol. 2004 Jul;78(14):7344-51 PMID: 15220407
  19. Processing of the Ebola virus glycoprotein by the proprotein convertase furin.
    Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7 PMID: 9576958
  20. HIV/AIDS: virus kept on a leash.
    Nature. 2008 Jan 24;451(7177):406-8 PMID: 18200012
  21. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?
    J Virol. 1996 Feb;70(2):820-9 PMID: 8551620
  22. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP.
    J Virol. 2002 May;76(10):4855-65 PMID: 11967302
  23. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor.
    Nature. 2008 Jul 10;454(7201):177-82 PMID: 18615077
  24. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.
    J Virol. 2006 Jun;80(11):5156-67 PMID: 16698996
  25. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Nature. 2008 Jan 24;451(7177):425-30 PMID: 18200009
  26. Ectodomain shedding of the glycoprotein GP of Ebola virus.
    EMBO J. 2004 May 19;23(10):2175-84 PMID: 15103332
  27. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
    Cell Host Microbe. 2007 Sep 13;2(3):193-203 PMID: 18005734
  28. Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein.
    Virology. 2009 Jan 20;383(2):237-47 PMID: 19013626
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2009-02-24
Epub
2009-00-28
Pages
2886-91
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC2650360
Subset
IM
Grants
NIAID NIH HHS · T32 AI007632 · United States
NIAID NIH HHS · R01 AI043455 · United States
NIGMS NIH HHS · T32 GM007229 · United States
NIAID NIH HHS · U54-AI57168 · United States
NIAID NIH HHS · T32-AI07632 · United States
NIGMS NIH HHS · T32-GM07229 · United States
NIAID NIH HHS · U01 AI070369 · United States
NIAID NIH HHS · T32 AI055400 · United States
NIAID NIH HHS · T32-AI55400 · United States
NIAID NIH HHS · U54 AI057168 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]